2. 您的位置
3. 首页
4. 会议论文
5. First-line tepotinib (MSC2156119J), an oral c-Met inhibitor, versus sorafenib in Asian patients with

First-line tepotinib (MSC2156119J), an oral c-Met inhibitor, versus sorafenib in Asian patients with

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：achiao172

【摘 要】

：

Background: HCC, a poor-prognosis disease for which the only approved drug is sorafenib, has a high unmet need.Factors associated with tumor aggressiveness in advanced HCC include c-Met amplification/

【作 者】

：

Shukui Qin Ho yeong Lim Baek-yeol Ryoo Cindy Li Huiling Xiong Andreas Johne Ann-lii Cheng 

【机 构】

：

Medical Oncology Department, Nanjing Bayi Hospital, Nanjing, China

【出 处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年4期

【关键词】

：

HCC 

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Background: HCC, a poor-prognosis disease for which the only approved drug is sorafenib, has a high unmet need.Factors associated with tumor aggressiveness in advanced HCC include c-Met amplification/over expression.

其他文献

Laparoscopic versus open abdominal peritoneal resection for rectal cancer: a case-matched study of p

Objective: The aim of the study is to evaluate the safety and feasibility of laparoscopic abdominal peritoneal resection (LAPR) for rectal cancer compared with conventional open abdominal peritoneal r

会议

Laparoscopicabdominal peritoneal resectionrectal

Evaluation of the frequency of MET Expression and Amplification in Chinese Hepatocellular Carcinoma

Objective: MET is a potential therapeutic target in hepatocellular carcinoma (HCC).This study evaluated MET expression and amplification in Chinese HCC patients and investigated the relationship with

会议

METHCC

Clinicopathological features and the prognostic factors of colorectal neuroendocrine neoplasms (NENs

Objective: The World Health Organization classifies neuroendocrine neoplasms of the colon and rectum together as a single entity, but there is significant difference observed between them.

会议

Colorectal neuroendocrine neoplasmsPrognostic fac

The influence of marital status on stage at diagnosis and survival of patients with colorectal neuro

Objective: Research indicates an association between marital status and health but this link hasnt been thoroughly explored.Our goal was to examine the association of marital status on the survival ou

会议

colorectal neuroendocrine neoplasmsmarital statusprognostic analysis

The result of Phase 1b and phase 2 study of selective VEGFR inhibitor fruquintinib as 3+ line therap

Objective: Fruquintinib is a novel oral small molecule compound selectively inhibits vascular endothelial growth factor receptors (VEGFR)1, 2, and 3 with potent inhibitory effects on multiple human tu

会议

FruquintinibmCRCPFS

Prospective Randomized Phase Ⅱ Study of FOLFIRI versus FOLFOX7 in Advanced Gastric Adenocarcinoma: a

Objective: The purpose was to compare folinic acid, 5-fluorouracil (5-FU), and irinotecan (mFOLFIRI;arm A) with folinic acid, 5-FU, and oxaliplatin (mFOLFOX7;arm B) as first-line treatments in patient

会议

Advanced Gastric AdenocarcinomaFOLFIRIFOLFOX7

Safety and efficacy of first-line tepotinib (MSC2156119J)in a phase Ⅰb trial in Asian patients with

Objective: The overall prognosis of advanced hepatocellular cancer (HCC) remains poor, with c-Met abnormalities associated with a particularly poor prognosis.The highly selective c-Met inhibitor tepot

会议

hepatocellular cancer

Nomogram and Recursive Partitioning Analysis to Determine the Risk of Cancer-Specific Survival for P

Objective: Whether adjuvant chemoradiotherapy (ACRT) or chemotherapy (ACT) will benefit for stage Ⅱ or Ⅲ upper rectal cancer (URC) after radical surgery remains unclear.

会议

upper rectal canceradjuvant chemoradiotherapyadj

Metabolic tumor burden: a new promising way to reach precise personalised treatment in PDAC

Objective: Pancreatic cancer is currently one of the deadliest solid malignancies and pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer.

会议

PDACpancreatic ductal adenocarcinomaMTB

An open-label, randomized, multicenter study of S-1 vs Gemcitabine in patient with advanced pancreat

Objective: Gemcitabine (GEM) is a standard treatment in patients with advanced pancreatic cancer (PC).S-1 has shown a good efficacy and well safety in Japanese patients from previous studies and has b

会议

Advanced pancreatic cancerS-1GEM